|
August 2007 Theracos initiates Phase II clinical trial to evaluate
the safety and effect of THR-4109 on weight loss in obese subjects over a 24-week treatment period
September 2006 Theracos awarded NIH Small Business Innovation
Research grant to study the ability of THR-0921 to reduce cardiovascular complications in diabetes
May 2006 Theracos acquires proprietary therapeutic platform in
the area of obesity and metabolic disease based on clinical
observations in a small physician-sponsored trial
February 2006 Theracos enters into agreement
with Osaka University
to study anti-inflammatory activity of THR-0921
December 2005 Theracos partner Egret Pharma Shanghai receives
clinical trial permit from SFDA in China
November 2005 Theracos-funded investigator
Philip Tsao of Stanford University and collaborators report their characterization of the anti-inflammatory
activity of the 921 class
(Tetsuya Tomita, Yoshimi Kakiuchi and Philip S. Tsao. Arthritis
Research & Therapy, 8:R7 2005)
October 2005 Theracos enters into research collaboration
agreement with Egret Pharma Shanghai to extend the scope of research
in China
August 2005 Theracos awarded NIH Small Business Innovation
Research grant to develop additional information on compounds to be
used for the treatment of diabetes
March 2005 Theracos completes Phase I pharmacokinetic crossover
study on improved formulation of anti-diabetic compound THR-0921
March 2004 Theracos enters into an agreement with Transpect, Ltd
for licensing of compounds developed in Japan
January 2004 Theracos enters into a discovery and development
agreement with Egret Pharma Shanghai Ltd. to develop compounds and
conduct clinical trials in the areas of diabetes and metabolic
disease
June 2003 Theracos enters into an agreement with the Research
Institute of Palo Alto Medical Foundation to support work in the
area of obesity and metabolic disease
May 2003 Theracos completes the acquisition of substantially all
of the assets of Calyx Therapeutics, Inc. “Calyx has done a
wonderful job of developing a platform for compound discovery and
development in the areas of metabolic disease and inflammation, two
areas of high interest to Theracos,” said Edward P. Amento, M.D.,
CEO of Theracos. “We are committed to continuing to develop and
expand their portfolio through clinical development and additional
discovery to further add value to these interesting assets.”
January 2003 Theracos enters into Sponsored Research Agreement
with Molecular Medicine Research Institute to carry out animal
studies in preclinical programs.
October 2002 Theracos and Discovery Partners International
announce extension and expansion of their drug discovery program.
"We are delighted to be consolidating our relationship with Theracos,"
stated Taylor Crouch, President and COO of Discovery Partners
International. "Our integrated drug discovery capabilities and
platforms are an excellent fit with Theracos's target expertise and
we look forward to achieving important drug development milestones
as we move forward in this exciting collaboration."
March 2002 Theracos, Inc. and Discovery Partners International,
Inc. enter into an agreement to discover novel lead compounds in the
area of metabolic disease
|
